Evidence map›Paper›PMID 34696475›Full record

ArticleViruses2021

In Vitro Evaluation of the Therapeutic Potential of Phage VA7 against Enterotoxigenic

Nata Bakuradze, Maya Merabishvili, Khatuna Makalatia, Elene Kakabadze, Nino Grdzelishvili, Jeroen Wagemans, Cedric Lood, Irakli Chachua, Mario Vaneechoutte, Rob Lavigne and 3 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Nata BakuradzeResearch & Development Department, George Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi 0160, Georgia.
Maya MerabishviliResearch & Development Department, George Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi 0160, Georgia.ORCID 0000-0002-2566-0772
Khatuna MakalatiaResearch & Development Department, George Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi 0160, Georgia.
Elene KakabadzeResearch & Development Department, George Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi 0160, Georgia.ORCID 0000-0001-8496-7849
Nino GrdzelishviliResearch & Development Department, George Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi 0160, Georgia.
Jeroen WagemansLaboratory of Gene Technology, Department of Biosystems, KU Leuven, 3001 Leuven, Belgium.ORCID 0000-0002-2185-5724
Cedric LoodLaboratory of Gene Technology, Department of Biosystems, KU Leuven, 3001 Leuven, Belgium.ORCID 0000-0001-7826-3378
Irakli ChachuaInstitute of Medical and Public Health Research, IIia State University, Tbilisi 0162, Georgia.
Mario VaneechoutteLaboratory Bacteriology Research, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-4586-203X
Rob LavigneLaboratory of Gene Technology, Department of Biosystems, KU Leuven, 3001 Leuven, Belgium.
Jean-Paul PirnayLaboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, 1120 Brussels, Belgium.ORCID 0000-0002-6863-5219
Ivane AbiatariInstitute of Medical and Public Health Research, IIia State University, Tbilisi 0162, Georgia.ORCID 0000-0002-1118-3477
Nina ChanishviliResearch & Development Department, George Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi 0160, Georgia.ORCID 0000-0002-7859-3032
George Eliava Institute of Bacteriophage, Microbiology and Virology · GEKU Leuven · BEGhent University · BETbilisi State Medical University · GEQueen Astrid Military Hospital · BETbilisi State University · GEUniversity Geomedi · GE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the beginning of the 20th century, bacteriophages (phages), i.e., viruses that infect bacteria, have been used as antimicrobial agents for treating various infections. Phage preparations targeting a number of bacterial pathogens are still in use in the post-Soviet states and are experiencing a revival in the Western world. However, phages have never been used to treat diseases caused by

Indexed as

BacteriophagesPhage TherapyBacteroides fragilisBacteroides InfectionsColonColorectal NeoplasmsDiarrheaEpithelial CellsHumansbacteriophagesCECcolonic epithelial cellscolorectal carcinomaCRCenterotoxigenic Bacteroides fragilisETBFin vitro modelphage therapy

Identifiers

PMID34696475
PMCPMC8538522
OpenAlexW3205164290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.